abstract |
The present invention prevents or treats fusion peptides that inhibit TLR1/2, TLR2/6, TLR7, TLR8 and TLR9 signaling pathways, and Toll-like receptors 4 (TLR4) and TLR3, and diseases mediated by TLR pathways. To a pharmaceutical composition for The fusion peptides of the present invention show excellent effect of inhibiting TLR4 and various TLR pathways, and are caused by various TLR pathway-mediated diseases such as autoimmune diseases, inflammatory diseases and It may be useful to prevent and treat neurodegenerative diseases by suppressing the TLR-mediated immune response. |